<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Novel candidates of biomarker and therapeutic target in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) were investigated using a proteomic approach </plain></SENT>
<SENT sid="1" pm="."><plain>The proteome of <z:mpath ids='MPATH_458'>normal</z:mpath> colorectal epithelial tissues was compared with that of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> ones in 59 CRC patients using two-dimensional difference gel electrophoresis </plain></SENT>
<SENT sid="2" pm="."><plain>Of 3458 protein spots, 110 exhibited statistically significant (p&lt;0.01) differences in intensity (more than 2.5-folds) between the <z:mpath ids='MPATH_458'>normal</z:mpath> and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue groups </plain></SENT>
<SENT sid="3" pm="."><plain>Of 67 unique gene products that were identified for 105 of the 110 protein spots, we focused on the higher expression of the <z:mpath ids='MPATH_270'>adenoma</z:mpath> <z:e sem="disease" ids="C0032580" disease_type="Neoplastic Process" abbrv="">polyposis coli</z:e>-binding protein EB1 (EB1) </plain></SENT>
<SENT sid="4" pm="."><plain>EB1 was originally discovered as a binding protein of APC, which is a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene product, and the expression of EB1 has been associated with poor prognosis in several <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> but not in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Immunohistochemical analysis of the 132 CRC cases revealed that EB1 was overexpressed in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in correlation with poor prognosis </plain></SENT>
<SENT sid="6" pm="."><plain>Suppression of EB1 by RNAi inhibited <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell proliferation and invasion </plain></SENT>
<SENT sid="7" pm="."><plain>In this study, the overexpression of EB1 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues correlating with prognosis, and its functional contribution to the malignant phenotypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells are described </plain></SENT>
<SENT sid="8" pm="."><plain>The present findings indicate that EB1 is a potential biomarker and therapeutic target in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>